Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

PrEP uptake in MSM who inject drugs is low, although research shows this group is at higher risk for HIV acquisition through ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

Margareth Mwakilasa, an assistant research fellow at Muhimbili University of Health and Allied Sciences in Tanzania and a PhD student in Global Health at University College Dublin, presented her ...

Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...

A University of New Mexico researcher and assistant professor is breaking barriers in the health community for fellow Native Americans. Hailing from the Diné Nation, Crystal Lee has been researching ...

You also need to undergo HIV testing before taking this medication. This article examines the effectiveness of Descovy for PrEP and how long it may take for the drug to start working. For more ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Early results on the drug levels achieved in women and the safety of the ... The most widely used form of PrEP is a daily HIV ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...